More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice
European Respiratory Journal · 2023
DOI: 10.1183/13993003.00865-2023 ↗Kurz gefasst
Editorial in der Zeitschrift European Respiratory Journal, 2023. Verfasst von Scott H Donaldson. Beteiligte Einrichtung: University of North Carolina at Chapel Hill School of Medicine, Division of Pulmonary and Critical Care Medicine, Chapel Hill, NC, USA scott_donaldso…. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 15 Literaturangaben.
Abstract (Originalsprache)
Tweetable abstract Higher concentrations of hypertonic saline provide greater protection against pulmonary exacerbation and respiratory symptom improvement in people with cystic fibrosis, and are generally well tolerated when delivered with rapid nebuliser systemshttps://bit.ly/3WPkFsy
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- University of North Carolina at Chapel Hill School of Medicine, Division of Pulmonary and Critical Care Medicine, Chapel Hill, NC, USA scott_donaldson@med.unc.edu.
ORCID-Profile: Scott H Donaldson
Zitieren
APA
Donaldson, S. H. (2023). More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice. European Respiratory Journal. https://doi.org/10.1183/13993003.00865-2023
Vancouver
Donaldson SH. More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice. European Respiratory Journal. 2023. doi:10.1183/13993003.00865-2023
BibTeX
@article{Donaldson2023,
author = {Donaldson, Scott H},
title = {More is better? Hypertonic saline dose and response for cystic fibrosis: efficacy, tolerability and implications for clinical practice},
journal = {European Respiratory Journal},
year = {2023},
doi = {10.1183/13993003.00865-2023}
}
EUVIMED